Covered recipient · General Payments record
CHAKRA P CHAULAGAIN
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$25,695.01
98 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,950.00 | 5 |
| Consulting Fee | $6,694.00 | 4 |
| Food and Beverage | $2,109.61 | 71 |
| Travel and Lodging | $941.40 | 18 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $17,983.68 | 28 |
| GENZYME CORPORATION | $3,586.95 | 6 |
| E.R. Squibb & Sons, L.L.C. | $2,130.00 | 1 |
| Janssen Research & Development, LLC | $745.42 | 12 |
| PFIZER INC. | $351.63 | 6 |
| GlaxoSmithKline, LLC. | $141.34 | 7 |
| Daiichi Sankyo Inc. | $111.74 | 5 |
| Novartis Pharmaceuticals Corporation | $84.97 | 5 |
| AstraZeneca Pharmaceuticals LP | $75.40 | 4 |
| TAIHO ONCOLOGY, INC. | $66.25 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $56.43 | 3 |
| BeiGene USA, Inc. | $50.39 | 3 |
| Stemline Therapeutics Inc. | $50.23 | 2 |
| Astellas Pharma US Inc | $41.20 | 2 |
| Merck Sharp & Dohme LLC | $31.59 | 2 |
| Regeneron Healthcare Solutions, Inc. | $26.80 | 1 |
| TerSera Therapeutics LLC | $24.20 | 1 |
| SERVIER PHARMACEUTICALS LLC | $23.00 | 1 |
| Genentech USA, Inc. | $22.77 | 1 |
| Cumberland Pharmaceuticals, Inc. | $21.56 | 1 |
| Tempus AI, Inc | $21.22 | 1 |
| EMD Serono, Inc. | $20.00 | 1 |
| Eisai Inc. | $15.80 | 1 |
| Janssen Scientific Affairs, LLC | $12.44 | 1 |
Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CHAKRA P CHAULAGAIN
NPI 1487824124 · CMS profile ID 1202560
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
WESTON, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1487824124?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CHAKRA P CHAULAGAIN, NPI 1487824124, CMS profile ID 1202560. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487824124?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). CHAKRA P CHAULAGAIN, NPI 1487824124, CMS profile ID 1202560. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487824124?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- CHAKRA P CHAULAGAIN, NPI 1487824124, CMS profile ID 1202560, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1487824124?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
98 matching records · $25,695.01 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–98 of 98.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc. | $19.81 | 07/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089407918 | CMS |
| PFIZER INC. | $20.44 | 07/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131347696 | CMS |
| Janssen Scientific Affairs, LLC | $12.44 | 07/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078848601 | CMS |
| Regeneron Healthcare Solutions, Inc. | $26.80 | 07/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114022792 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.14 | 07/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104757664 | CMS |
| Janssen Biotech, Inc. | $3,575.00 | 06/17/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078519718 | CMS |
| Novartis Pharmaceuticals Corporation | $13.18 | 06/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086722041 | CMS |
| Janssen Research & Development, LLC | $38.44 | 06/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077587793 | CMS |
| Janssen Research & Development, LLC | $57.64 | 06/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077587797 | CMS |
| Janssen Research & Development, LLC | $20.98 | 06/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077587801 | CMS |
| Janssen Research & Development, LLC | $20.98 | 06/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077587805 | CMS |
| Janssen Research & Development, LLC | $216.02 | 06/04/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077587809 | CMS |
| Janssen Research & Development, LLC | $131.65 | 06/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077587811 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.13 | 05/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104294446 | CMS |
| TAIHO ONCOLOGY, INC. | $21.64 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137940504 | CMS |
| Janssen Biotech, Inc. | $13.17 | 05/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078519131 | CMS |
| GENZYME CORPORATION | $18.79 | 05/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139810219 | CMS |
| BeiGene USA, Inc. | $15.91 | 04/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120849360 | CMS |
| Daiichi Sankyo Inc. | $21.04 | 04/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089407916 | CMS |
| Stemline Therapeutics Inc. | $25.95 | 04/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1142958916 | CMS |
| Janssen Biotech, Inc. | $126.23 | 04/08/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078518896 | CMS |
| Janssen Biotech, Inc. | $7.35 | 04/08/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078519147 | CMS |
| Janssen Biotech, Inc. | $4,125.00 | 04/05/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078519069 | CMS |
| PFIZER INC. | $20.19 | 04/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131313441 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.90 | 04/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137508591 | CMS |
| Janssen Biotech, Inc. | $198.68 | 03/28/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078519528 | CMS |
| Janssen Biotech, Inc. | $4.78 | 03/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078518949 | CMS |
| Janssen Biotech, Inc. | $123.97 | 03/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078519044 | CMS |
| Janssen Biotech, Inc. | $22.61 | 03/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078519049 | CMS |
| EMD Serono, Inc. | $20.00 | 03/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120227590 | CMS |
| PFIZER INC. | $122.61 | 03/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1130908102 | CMS |
| Daiichi Sankyo Inc. | $18.86 | 03/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089407914 | CMS |
| Janssen Biotech, Inc. | $5.50 | 03/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078518928 | CMS |
| TAIHO ONCOLOGY, INC. | $21.64 | 03/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137936707 | CMS |
| GlaxoSmithKline, LLC. | $21.64 | 03/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115930393 | CMS |
| Cumberland Pharmaceuticals, Inc. | $21.56 | 02/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146400048 | CMS |
| GENZYME CORPORATION | $158.71 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139810223 | CMS |
| GENZYME CORPORATION | $3,324.00 | 02/26/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139810225 | CMS |
| GENZYME CORPORATION | $24.59 | 02/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139810227 | CMS |
| GENZYME CORPORATION | $48.64 | 02/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139810229 | CMS |
| Janssen Biotech, Inc. | $1,100.00 | 02/23/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078519095 | CMS |
| Merck Sharp & Dohme LLC | $14.13 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141920126 | CMS |
| BeiGene USA, Inc. | $16.66 | 02/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120849362 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.21 | 02/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137508587 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.41 | 01/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104202779 | CMS |
| PFIZER INC. | $17.82 | 01/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1130895006 | CMS |
| Genentech USA, Inc. | $22.77 | 01/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132985821 | CMS |
| Astellas Pharma US Inc | $22.83 | 01/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139288984 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $941,664.20 | 69 |
| PY2024 | Principal investigator | $492,010.28 | 44 |
| PY2023 | Principal investigator | $488,703.26 | 57 |
| PY2022 | Principal investigator | $207,108.60 | 20 |
| PY2021 | Principal investigator | $120,138.00 | 23 |
| PY2020 | Principal investigator | $101,964.00 | 23 |
| PY2019 | Principal investigator | $47,018.00 | 9 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
69 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $660.00 | 12/29/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175398840 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,691.64 | 12/26/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. | No dispute reported | 06/30/2026 | 1175398825 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,572.00 | 12/25/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. | No dispute reported | 06/30/2026 | 1175398820 |
| Principal investigator 1 | Janssen Research & Development, LLC | $67,326.00 | 12/25/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. | No dispute reported | 06/30/2026 | 1175399118 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,139.00 | 12/15/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175399065 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $23,076.00 | 11/26/2025 | Non-covered Recipient Entity Cleveland Clinic Florida Aetna Aco | A study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | No dispute reported | 06/30/2026 | 1235998118 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $11,317.50 | 11/26/2025 | Non-covered Recipient Entity Cleveland Clinic Florida Aetna Aco | A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) | No dispute reported | 06/30/2026 | 1235998120 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,139.00 | 11/24/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175398854 |
| Principal investigator 1 | ABBVIE INC. | $3,300.00 | 11/20/2025 | Non-covered Recipient Entity CLEVELAND CLINIC OF FLORIDA | A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202524808 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $9,824.00 | 11/20/2025 | Non-covered Recipient Entity Cleveland Clinic Florida Aetna Aco | A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1235998122 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,450.00 | 11/17/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide | No dispute reported | 06/30/2026 | 1175399088 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,962.00 | 11/10/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. | No dispute reported | 06/30/2026 | 1175399149 |
| Principal investigator 1 | Janssen Research & Development, LLC | $475.00 | 11/06/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175398904 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25,770.63 | 11/03/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. | No dispute reported | 06/30/2026 | 1175398988 |
| Principal investigator 1 | Janssen Research & Development, LLC | $23,848.00 | 10/31/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. | No dispute reported | 06/30/2026 | 1175398847 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,670.00 | 10/24/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175398911 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,050.00 | 10/20/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. | No dispute reported | 06/30/2026 | 1175399072 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,205.00 | 10/20/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. | No dispute reported | 06/30/2026 | 1175399102 |
| Principal investigator 1 | Janssen Research & Development, LLC | $27,746.60 | 10/20/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. | No dispute reported | 06/30/2026 | 1175399125 |
| Principal investigator 1 | Celgene Corporation | $32,771.00 | 10/08/2025 | Non-covered Recipient Entity Cleveland Clinic Florida Weston | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | No dispute reported | 06/30/2026 | 1222304503 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,550.00 | 10/03/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide | No dispute reported | 06/30/2026 | 1175398900 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,100.00 | 10/03/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide | No dispute reported | 06/30/2026 | 1175399023 |
| Principal investigator 1 | Janssen Research & Development, LLC | $26,087.41 | 10/02/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. | No dispute reported | 06/30/2026 | 1175398981 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,000.00 | 09/29/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175399042 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,906.00 | 09/22/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or | No dispute reported | 06/30/2026 | 1175398888 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,550.00 | 09/19/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175398940 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,550.00 | 09/19/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175398964 |
| Principal investigator 1 | Janssen Research & Development, LLC | $650.00 | 09/19/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175399047 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,290.00 | 09/19/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175399114 |
| Principal investigator 1 | Janssen Research & Development, LLC | $370.00 | 09/04/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175398928 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,025.00 | 09/01/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175399083 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,670.00 | 08/25/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175398970 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,360.00 | 08/21/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175398830 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $27,287.80 | 08/19/2025 | Non-covered Recipient Entity Cleveland Clinic Florida | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190329119 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,425.00 | 08/08/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175398917 |
| Principal investigator 1 | BeOne Medicines Ltd. | $33,536.00 | 07/31/2025 | Non-covered Recipient Entity Cleveland Clinic Florida | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190330465 |
| Principal investigator 1 | Janssen Research & Development, LLC | $185.00 | 07/28/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175399145 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,050.00 | 07/24/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175398958 |
| Principal investigator 1 | Janssen Research & Development, LLC | $41,150.00 | 07/18/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or | No dispute reported | 06/30/2026 | 1175398883 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,800.00 | 07/14/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175399092 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,550.00 | 06/23/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175398863 |
| Principal investigator 1 | Celgene Corporation | $26,700.00 | 06/04/2025 | Non-covered Recipient Entity Cleveland Clinic Florida Weston | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | No dispute reported | 06/30/2026 | 1222304577 |
| Principal investigator 1 | Celgene Corporation | $45,270.00 | 06/02/2025 | Non-covered Recipient Entity Cleveland Clinic Florida Weston | A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1222304493 |
| Principal investigator 1 | Janssen Research & Development, LLC | $660.00 | 05/30/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175399130 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,080.00 | 05/26/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175398878 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,280.00 | 05/26/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175399053 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,554.00 | 05/19/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175399000 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,775.00 | 04/28/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175398893 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $76,736.70 | 04/23/2025 | Non-covered Recipient Entity CLEVELAND CLINIC WESTON | A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients with Stage IIIa AL Cardiac Amyloidosis. | No dispute reported | 06/30/2026 | 1185542286 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,140.00 | 04/21/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175399028 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $40,062.60 | 04/02/2025 | Non-covered Recipient Entity CLEVELAND CLINIC WESTON | A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients with Stage IIIb AL Cardiac Amyloidosis. | No dispute reported | 06/30/2026 | 1185542288 |
| Principal investigator 1 | Janssen Research & Development, LLC | $370.00 | 03/31/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175398836 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,466.00 | 03/24/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175398994 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,035.00 | 03/20/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175398858 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25,525.90 | 03/17/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175399160 |
| Principal investigator 1 | Janssen Research & Development, LLC | $26,829.00 | 03/10/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175398945 |
| Principal investigator 1 | Janssen Research & Development, LLC | $475.00 | 03/06/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175399034 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,280.00 | 03/03/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175398933 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $33,288.30 | 02/25/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients with Stage IIIb AL Cardiac Amyloidosis. | No dispute reported | 06/30/2026 | 1185542290 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,100.00 | 02/24/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1175398868 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,350.00 | 02/20/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175399059 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $2,981.34 | 02/18/2025 | Non-covered Recipient Entity CLEVELAND CLINIC WESTON | A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients with Stage IIIa AL Cardiac Amyloidosis. | No dispute reported | 06/30/2026 | 1185542284 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $1,992.06 | 02/18/2025 | Non-covered Recipient Entity CLEVELAND CLINIC WESTON | A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients with Stage IIIb AL Cardiac Amyloidosis. | No dispute reported | 06/30/2026 | 1185542292 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,241.00 | 02/10/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175399012 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $6,410.92 | 01/27/2025 | Covered Recipient Teaching Hospital Cleveland Clinic Hospital | A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) | No dispute reported | 06/30/2026 | 1236001529 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,200.00 | 01/27/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | No dispute reported | 06/30/2026 | 1175398952 |
| Principal investigator 1 | Celgene Corporation | $54,011.00 | 01/24/2025 | Non-covered Recipient Entity Cleveland Clinic Florida Weston | A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1222304535 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $34,098.30 | 01/08/2025 | Non-covered Recipient Entity CLEVELAND CLINIC FLORIDA | A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients with Stage IIIa AL Cardiac Amyloidosis. | No dispute reported | 06/30/2026 | 1185542282 |
| Principal investigator 1 | Celgene Corporation | $80,666.50 | 01/08/2025 | Non-covered Recipient Entity Cleveland Clinic Florida Weston | A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) | No dispute reported | 06/30/2026 | 1222304487 |